Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

INTRODUCTION: Chronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become resistant to these treatments over time. CB-839...

Descripción completa

Detalles Bibliográficos
Autores principales: Timofeeva, Natalia, Ayres, Mary L., Baran, Natalia, Santiago-O’Farrill, Janice M., Bildik, Gamze, Lu, Zhen, Konopleva, Marina, Gandhi, Varsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203524/
https://www.ncbi.nlm.nih.gov/pubmed/37228498
http://dx.doi.org/10.3389/fonc.2023.1161254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203524/
https://www.ncbi.nlm.nih.gov/pubmed/37228498
http://dx.doi.org/10.3389/fonc.2023.1161254

Ejemplares similares